Raveena Nalla, MD
Endocrinology, Diabetes & Metabolism · Oxford, MSNPI 1679095772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,995, more than ten times the $148 reported in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MS, where the typical reported total is $4,678.
Across 240 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$565
- Xeris Pharmaceuticals, Inc.$415
- Boehringer Ingelheim$404
- Lilly USA, LLC$322
- Sequel Med Tech, LLC$275
- Dexcom, Inc.$271
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,678100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 29 | $565 |
| Xeris Pharmaceuticals, Inc. | 24 | $415 |
| Boehringer Ingelheim | 26 | $404 |
| Lilly USA, LLC | 19 | $322 |
| Sequel Med Tech, LLC | 6 | $275 |
| Dexcom, Inc. | 17 | $271 |
| Novo Nordisk | 14 | $265 |
| Amgen(2 entities) | 15 | $263 |
| Insulet Corporation | 8 | $239 |
| Recordati_rare_diseases_inc. | 10 | $211 |
| AbbVie | 13 | $199 |
| Medtronic | 7 | $197 |
| Abbott | 10 | $197 |
| Sanofi-aventis U.S. LLC | 10 | $186 |
| Pfizer | 5 | $102 |
| Tandem Diabetes Care, Inc. | 5 | $94 |
| IBSA Pharma Inc. | 4 | $92 |
| Bayer | 4 | $68 |
| Nevro Corp. | 2 | $52 |
| Kyowa Kirin, Inc. | 2 | $48 |
| Mannkind Corporation | 2 | $43 |
| AstraZeneca(2 entities) | 2 | $41 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Chiesi USA, Inc. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TWIIST$147
How this compares
$4,678 in reported general payments places this provider in the 50th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $93,288 |
| MounjaroTirzepatide | 71 | $87,527 |
| JardianceEmpagliflozin | 99 | $67,731 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $41,908 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 34 | $19,751 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 31 | $19,042 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $9,895 |
| FiaspInsulin Aspart (Niacinamide) | 14 | $8,720 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $7,826 |
| FarxigaDapagliflozin Propanediol | 13 | $7,355 |
| Novolog FlexpenInsulin Aspart | 28 | $7,009 |
| SynthroidLevothyroxine Sodium | 127 | $6,788 |
| Cinacalcet Hcl | 26 | $6,114 |
| TradjentaLinagliptin | 12 | $6,016 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $5,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp | $265 | $102,00894 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $404 | $93,498145 claims |
| Lilly USA, LLCMounjaro | $322 | $87,52771 claims |
| AstraZenecaFarxiga | $41 | $7,35513 claims |
| AbbVieSynthroid | $199 | $6,788127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Oxford
- Anitha GondhiOxford$2K
- Eric DyessJackson$885K
- Mark BorcheltGulfport$722K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
- Amanda SchieferJackson$204K
- Delali BlavoSouthaven$148K
- Richard GallowayHattiesburg$109K
- James PowellHattiesburg$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.